Predicting Liraglutide Weight Loss Response Using Brain Scans for Obesity

Obesity is a complex chronic disease characterized by excessive body fat, leading to significant health risks including type 2 diabetes, cardiovascular disease, and certain cancers. Liraglutide (Saxenda®), a GLP-1 receptor agonist, is an effective medication for weight management, but individual responses can vary significantly. This study addresses the crucial knowledge gap of predicting which patients will respond best to Liraglutide therapy, aiming to personalize treatment approaches.

While the detailed results of this completed trial are not yet publicly available, the study successfully completed its intervention phase with 73 enrolled participants. The primary objective was to determine if baseline fMRI-based food cue reactivity could serve as a predictive biomarker for weight loss outcomes with Liraglutide. The trial aimed to identify specific neural signatures that differentiate individuals who achieve significant weight loss from those who do not. > The core hypothesis was that individuals exhibiting particular patterns of brain activation in response to food cues would demonstrate a quantitatively different weight loss response to Saxenda® over the 16-week treatment period. Future publications are expected to provide the specific statistical correlations, p-values, and percentage weight changes observed between the treatment and placebo groups, as well as the predictive accuracy of fMRI.